May 24, 2023 03:08 PM EDT

Novo Nordisk makes the case it’s more than Wegovy in new corporate ad campaign

Beth Snyder Bulik

Senior Editor

While social media is abuzz witth Novo Nordisk’s diabetes and obesity medicines Ozempic and Wegovy, it’s probably safe to say far fewer TikTokers and Instagrammers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk makes the case it’s more than Wegovy in new corporate ad campaign

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

No­vo Nordisk makes the case it’s more than We­govy in new cor­po­rate ad cam­paign

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Novo Nordisk makes the case it’s more than Wegovy in new corporate ad campaign